In the latest trading session, 0.6 million Clearside Biomedical Inc (NASDAQ:CLSD) shares changed hands as the company’s beta touched 2.30. With the company’s most recent per share price at $1.27 changing hands around $0.12 or 10.43% at last look, the market valuation stands at $94.93M. CLSD’s current price is a discount, trading about -66.93% off its 52-week high of $2.12. The share price had its 52-week low at $0.65, which suggests the last value was 48.82% up since then. When we look at Clearside Biomedical Inc’s average trading volume, we note the 10-day average is 2.66 million shares, with the 3-month average coming to 667.85K.
Analysts gave the Clearside Biomedical Inc (CLSD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CLSD as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Clearside Biomedical Inc’s EPS for the current quarter is expected to be -0.12.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Clearside Biomedical Inc (NASDAQ:CLSD) trade information
Instantly CLSD is in green as seen in intraday trades today. With action 6.72%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 8.55%, with the 5-day performance at 6.72% in the green. However, in the 30-day time frame, Clearside Biomedical Inc (NASDAQ:CLSD) is -3.05% down. Looking at the short shares, we see there were 0.26 million shares sold at short interest cover period of 0.65 days.
Clearside Biomedical Inc (CLSD) estimates and forecasts
Data shows that the Clearside Biomedical Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -9.93% over the past 6 months, a -5.66% in annual growth rate that is considerably lower than the industry average of 17.20%. Year-over-year growth is forecast to reach -93.30% down from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 120k. 7 analysts are of the opinion that Clearside Biomedical Inc’s revenue for the current quarter will be 120k. The company’s revenue for the corresponding quarters a year ago was 859k and 6.34M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -86.00%. The estimates for the next quarter sales put growth at -98.10%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 27.88%. The 2024 estimates are for Clearside Biomedical Inc earnings to increase by 6.74%.
CLSD Dividends
Clearside Biomedical Inc is expected to release its next quarterly earnings report on 2024-Nov-11.
Clearside Biomedical Inc (NASDAQ:CLSD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 7.39% of Clearside Biomedical Inc shares while 26.33% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 28.43%. There are 26.33% institutions holding the Clearside Biomedical Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 4.0656% of the shares, roughly 2.84 million CLSD shares worth $3.69 million.
ROSALIND ADVISORS, INC. holds the second largest percentage of outstanding shares, with 3.7115% or 2.59 million shares worth $3.37 million as of 2024-06-30.
